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Abstract
Background: General practitioners (GPs) should regularly review patients’ medications and, if necessary,
deprescribe, as inappropriate polypharmacy may harm patients’ health. However, deprescribing can be challenging
for physicians. This study investigates GPs’ deprescribing decisions in 31 countries.
Methods: In this case vignette study, GPs were invited to participate in an online survey containing three clinical
cases of oldest-old multimorbid patients with potentially inappropriate polypharmacy. Patients differed in terms of
dependency in activities of daily living (ADL) and were presented with and without history of cardiovascular disease
(CVD). For each case, we asked GPs if they would deprescribe in their usual practice. We calculated proportions of
GPs who reported they would deprescribe and performed a multilevel logistic regression to examine the
association between history of CVD and level of dependency on GPs’ deprescribing decisions.
Results: Of 3,175 invited GPs, 54% responded (N = 1,706). The mean age was 50 years and 60% of respondents
were female. Despite differences across GP characteristics, such as age (with older GPs being more likely to take
deprescribing decisions), and across countries, overall more than 80% of GPs reported they would deprescribe the
dosage of at least one medication in oldest-old patients (> 80 years) with polypharmacy irrespective of history of
CVD. The odds of deprescribing was higher in patients with a higher level of dependency in ADL (OR =1.5, 95%CI
1.25 to 1.80) and absence of CVD (OR =3.04, 95%CI 2.58 to 3.57).
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Interpretation: The majority of GPs in this study were willing to deprescribe one or more medications in oldest-old
multimorbid patients with polypharmacy. Willingness was higher in patients with increased dependency in ADL
and lower in patients with CVD.
Keywords: Deprescribing, Polypharmacy, Multimorbidity, Primary health care, Old age,
Background
Polypharmacy, commonly defined as the concurrent use
of 5 or more medications, is a growing concern in a con-
text of common overtreatment. More than 40% of older
adults aged 65 years and over and an even higher per-
centage of older nursing home residents have polyphar-
macy [1, 2]. Polypharmacy can be problematic as it is
associated with a higher risk of being prescribed poten-
tially inappropriate medications (PIMs) [3]. One third of
adults aged 65 years and over are taking at least one
PIM [4]. Polypharmacy and PIMs are linked to an in-
creased risk of adverse drug events [5, 6], drug-drug and
drug-disease interactions [7, 8], functional decline [9–
11], decline in cognitive function [10, 12], increased risk
for falls [13, 14], and increase in direct medical health-
care costs [15].
Older multimorbid adults with cardiovascular diseases
(CVD) have been shown to be disproportionately af-
fected by medication-related issues [16]. Due to these
potential negative consequences optimizing polyphar-
macy in older adults including those with CVD is highly
relevant.
With increasing age the main treatment goals often
shift from the prevention of mortality and morbidity to
the maintaining of functional independence and quality
of life, especially in less robust older adults with limited
levels of independence [17]. In addition, the benefit-risk
profile of older dependent and less robust adults is al-
tered as they are at greater risk of medication induced
harm and may not have sufficient remaining life span to
benefit from preventive medications [18, 19]. Therefore,
older adults with limited functional independence might
particularly benefit from medication optimization
through deprescribing. However, little is currently
known about general practitioners’ (GPs) attitudes to-
wards deprescribing in patients with and without history
of cardiovascular disease or in those with limited func-
tional independence.
In recent years, deprescribing has become a popular
“new word to guide medication review” [20]. It is com-
monly defined as ‘the process of withdrawal or [reduc-
tion] of an inappropriate medication, supervised by a
healthcare professional with the goal of managing poly-
pharmacy and improving outcomes’ [21]. Deprescribing
has several benefits, such as achieving better health out-
comes through resolving adverse drug reactions, better
medication adherence, and direct medical healthcare
costs reductions [22]. However, deprescribing may also
have negative consequences, such as withdrawal reac-
tions and the worsening or return of medical conditions.
These potential harms can be minimized with appropri-
ate planning, monitoring, and re-initiation of medica-
tions if needed [22]. As evidenced by the high
prevalence of inappropriate medication use in older
adults, deprescribing is not routinely conducted in prac-
tice. Despite its potential benefits, deprescribing is diffi-
cult to implement [23]. In practice, both physicians and
patients report barriers to deprescribing, such as uncer-
tainty on how to deprescribe due to a lack of evidence-
based guidelines. Patients have reported believing that
their medications are still necessary or beneficial [24–
27]. An understanding of GPs’ deprescribing decisions
and the potential barriers they face is needed to inform
GP education and develop interventions to optimise ap-
propriate medication use in older adults.
In a case vignette study with 157 GPs in
Switzerland, we found a high rate of hypothetical
deprescribing of certain medications, which was influ-
enced by patients' history of CVD [28]. However, we
were not able to establish the generalisability of these
results and the influence of other patient characteris-
tics on GPs deprescribing decisions. Therefore, the
aim of this study was to examine deprescribing deci-
sions of GPs in oldest-old patients (80 years and over)
with polypharmacy across different countries and to
examine whether increasing levels of dependency in
activities of daily living (ADL) and history of CVD in-
fluenced these decisions.
Methods
Setting and study design
This is a cross-sectional case vignette study con-
ducted with GPs from 31 countries (see Fig. 1). It is
part of the LESS (barriers and enabLers to willing-
nESs to depreScribing in older patients with
multimorbidity and polypharmacy and their General
Practitioners) study.
Participants
Our total sample consisted of 3,175 GPs from 31 coun-
tries who were invited to participate by email through
national coordinators. Participants had previously
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provided consent to be contacted with opportunities to
participate in future research [29, 30]. Participants were
eligible for inclusion if they were practicing GPs.
Questionnaire
We used the same questionnaire as described in Man-
telli et al. (2018), but we included additional case vi-
gnettes [28]. We used the Checklist for Reporting Results
of Internet E-Surveys (CHERRIES) guidelines for report-
ing results of internet e-surveys [31, 32]. The question-
naire had 3 parts: 1) GP characteristics, 2) 3 case
vignettes of oldest-old patients with higher/heightened
dependency in activities of daily living (ADL) including
increasing cognitive impairment, each presented with
and without history of CVD, and 3) Likert-scale ques-
tions concerning factors influencing GPs’ deprescribing
decisions. For the complete questionnaire, refer to Add-
itional file 1: Appendix 1. Where necessary, national co-
ordinators translated and back-translated the survey
from English into 22 languages. In Finland and Israel,
the survey was distributed in English. In all other coun-
tries the survey was distributed in one or several national
languages (see Additional file 1: Appendix 2 for more in-
formation on survey languages). The online survey was
distributed and administered with SurveyMonkey (Palo
Alto, CA, USA).
To sample the participating GPs, first, we engaged
with national coordinators through the European Gen-
eral Practice Research Network (EGPRN). Second, na-
tional coordinators identified relevant networks through
which the survey could be distributed. Available net-
works varied depending on the country. Most national
coordinators did a convenience sampling in which they
distributed the survey by email to GPs in their personal
networks, who had previously consented to be invited to
participate in research. Participation was voluntary. In
some countries, the survey was sent to lists of GPs avail-
able at primary care research institutes or professional
societies, which explains the bigger sample size in these
countries. Reminders were used when necessary (max-
imum two reminders where sent). The response rate for
each country can be found in Additional file 1: Appendix
2. In Ukraine the survey was administered on paper dur-
ing a national GP conference due to infrastructure-
related reasons. We collected responses from February
to December 2018.
Our research team, largely composed of GPs, designed
the case vignettes with the aim of creating hypothetical
patients aged ≥80 years representing patients typically
seen in primary care. Repeated meetings to discuss the
case vignettes were held. Collaborators in other coun-
tries were consulted by email, with changes made as ne-
cessary. Before starting the data collection, the online
questionnaire was piloted among five Swiss GPs to test
its content validity. Before starting the data collection in
each participating country, each national coordinator
checked and, if applicable, adapted the layout of the sur-
vey based on the local context.
A
B
Fig. 1 Per country average of the percentage of case vignettes in
which GPs (N = 1,706) reported they would deprescribe at least one
(map A) vs. at least two (map B) medications. List of participating
countries (alphabetical order): Austria, Belgium, Bosnia and
Herzegovina, Brazil, Bulgaria, Croatia, Czech Republic, Denmark,
United Kingdom, Estonia, Finland, France, Germany, Greece,
Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Macedonia, the
Netherlands, New Zealand, Poland, Portugal, Romania, Slovenia,
Spain, Sweden, Switzerland, Ukraine. Maps designed by and adapted
from PresentationGO.com / © Copyright PresentationGO.com
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The case vignettes were identical except for CVD sta-
tus and levels of dependency in ADL. We provided de-
scriptions of dependency related to low, medium and
high impairment of ADL and cognitive function. All
hypothetical patients were prescribed the same medica-
tions. For every case vignette, we asked GPs whether
they would stop/reduce the dosage of at least one medi-
cation (i.e. deprescribe), and if so which one(s). GPs
were instructed to respond as to how they would act in
their usual practice.
In part 3 of the questionnaire, GPs were asked to rate
the importance of sixteen factors that potentially influ-
enced their deprescribing behaviour using 5-point
Likert-scales ranging from “not important” to “very im-
portant”. The selection of these factors was based on
work done by Luymes et al. [33] and Anderson et al.
[34] and was completed with factors based on our team’s
experience.
Completion of the survey took 10–15minutes. The dif-
ferent parts of the questionnaire were presented on differ-
ent pages and where necessary the content of one part
was distributed over different pages to keep the number of
items per page small. Respondents were able to navigate
back and forth through the survey. The national coordina-
tors sent a web link to GPs, which was required to access
the survey. The selection of one response option was
enforced. We did not use cookies nor did we collect IP ad-
dresses. We did not perform a timestamp analysis.
Statistical analyses
We described GP characteristics by calculating propor-
tions, means, and confidence intervals (CI). We calcu-
lated crude odds ratios (OR) from univariate logistic
regressions to determine if GP characteristics were asso-
ciated with decisions to deprescribe. For each case vi-
gnette we described the proportions of GPs who would
deprescribe. As a sensitivity analysis, we also performed
this analysis in countries with a > 60% response rate. We
calculated the average number of medications depre-
scribed per case vignette. We performed a multilevel lo-
gistic regression to examine the association between
both history of CVD and level of dependency in ADL
and GPs’ decisions to deprescribe at least one medica-
tion in any of the case vignettes by accounting for the
clustering of GPs at country level. We adjusted the
model for the following GP characteristics: age, sex,
average number of consultations per day, frequency of
seeing patients with polypharmacy. Subsequently, we
performed a comparison of proportions to determine
whether GPs’ deprescribing decisions concerning spe-
cific medications changed with increased patient de-
pendency. Lastly, for the factors included in the Likert-
scales we calculated the percentage of GPs who rated
these factors as (very) important. We defined a two-
sided p-value of < 0.05 as significant. All analyses were




In the participating countries, the median response rate
was 50% (range: 11–95%). Of the total of 3,175 invited
GPs across countries, 1,706 responded (54%), and 1415
GPs completed the whole questionnaire. The number of
participants differed by country (range: 20 in Czech Re-
public and Ireland; 247 in Hungary).
Table 1 presents characteristics of the participating
GPs. 60% were female, mean age was 50 years, and the
mean clinical experience as GP was 18 years. As shown
in this table, being female reduced the odds of depre-
scribing in all case vignettes (compared to not depre-
scribing in one or more case vignettes), whereas the
odds of deprescribing increased with increasing age of
GPs, with GPs regularly treating patients aged 70 years
or more with polypharmacy and with GPs regularly deal-
ing with the topic of deprescribing.
Deprescribing decisions
Table 2 shows the percentage of GPs reporting stopping
at least one, two or three medications per case vignette.
More than 90% (range: 94–95%) of GPs reported that
they would deprescribe at least one medication in all the
case vignettes without history of CVD whereas the pro-
portion was slightly lower (range: 82–90%) in the case
vignettes with history of CVD. Around 70% of GPs
(range: 68–78%) opted for deprescribing at least 3 medi-
cations in the case vignettes without CVD history while
the percentage again was lower (range: 27–59%) in the
case vignettes with CVD history. In CVD cases, the pro-
portion of GPs who reported deprescribing medications
increased with increasing dependency levels. The sensi-
tivity analysis performed in countries with a response
rate > 60% showed the same trends (Additional file 1:
Appendix 3).
The multilevel logistic regression model of GPs’ deci-
sions to deprescribe at least one medication in any case
vignette, adjusted for GP characteristics, showed that the
odds of GPs reporting deprescribing in patients without
CVD history were 3 times higher than the odds of GPs
reporting to deprescribe in patients with history of CVD
(Table 3). The odds of GPs reporting deprescribing in
the scenarios with an increased level of dependency were
1.29 to 1.50 times higher than the odds of GPs reporting
deprescribing in the scenarios in which patients had
lower dependency levels. While GPs’ age was associated
with taking deprescribing decisions (OR: 1.14 for 10-year
increase, 95% CI: 1.06–1.23), female sex was not (OR:
0.89, 95% CI: 0.75–1.05) nor were the average number
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of consultations per day or the frequency of seeing pa-
tients with polypharmacy (Table 3).
Geographical variation
Figure 1 maps the differences in the per country aver-
ages of case vignettes in which GPs from our conveni-
ence sample opted for deprescribing in at least one
versus at least two medications. The percentages of
deprescribing a minimum of one medication ranged
from 77% in Bulgaria to 100% in Ukraine, whereas the
percentages of deprescribing a minimum of two medica-
tions ranged from 58% in Bulgaria to 92% in Denmark.
Both maps show variation across countries.
Deprescribing decisions by medication type
Table 4 shows the proportion of GPs who would depre-
scribe sorted by medication type, CVD history, and level
of dependency in ADL. There was little variation in
Table 1 Baseline characteristics of general practitioners (GPs) from all participating countries (N countries = 31, N GPs = 1,706)
GPs’ deprescribing decisionsa
(N = 1,428, only complete records)
GP characteristics Overall Deprescribing in < 6 case
vignettes
(n = 370)
Deprescribing in all 6 case
vignettesb
(n = 1,058)






female, n (%) 1,021
(60)
240 (65) 593 (56) 0.74 (0.57 to 0.96) 0.024
male, n (%) 685
(40)




50 (12) 49 (12) 50 (12) per 10 years:
1.14 (1.02 to 1.28)
0.020





17 (11) 18 (11) per 10 years:
1.12 (1.00 to 1.25)
0.055
Average number of consultations per working day, n (%)
< 15 197
(12)
31 (8) 121 (11) ref. –
15–25 567
(33)
123 (33) 356 (34) 0.78 (0.48 to 1.25) 0.30
26–35 468
(27)
93 (25) 300 (28) 0.91 (0.56 to 1.50) 0.72
> 35 474
(28)
123 (33) 281 (27) 0.71 (0.43 to 1.20) 0.21





310 (84) 942 (89) 1.63 (1.15 to 2.32) 0.006




60 (16) 116 (11) ref. –





176 (48) 638 (60) 1.53 (1.18 to 1.97) 0.001




194 (52) 420 (40) ref. –





76 (21) 305 (29) 1.46 (1.09 to 1.97) 0.012




294 (79) 753 (71) ref. -
adeprescribing defined as stopping or reducing the dosage of at least one medication; bmedian deprescribing behaviour corresponds to deprescribing or
reducing the dosage of at least one medication in all of the 6 hypothetical patients; ccrude odds ratios from multilevel univariate logistic regression; dP-values
from univariate logistic regression
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reported deprescribing for pantoprazole, tramadol, and
paracetamol among the different levels of dependency
and CVD history. For atorvastatin, aspirin, amlodipine,
and enalapril the percentages of GPs reporting to depre-
scribe generally increased with increasing levels of de-
pendency and was lower when there was a history of
CVD. Overall, GPs were most likely to deprescribe
proton-pump inhibitors and pain medication.
Factors important for deprescribing decisions
Figure 2 shows the importance given to different factors
reported to impact GPs’ deprescribing decisions. Risks
and benefits of medications, patients’ quality of life, pa-
tients’ life expectancy and patients’ fear of potential
negative health outcomes were important or very im-
portant to more than 90% of GPs. Less than half of GPs
rated the time needed for deprescribing as important or
very important for making deprescribing decisions.
Discussion
In this study of over 1,700 GPs from 31 countries, we in-
vestigated GPs’ deprescribing decisions in oldest-old pa-
tients with polypharmacy. Despite differences across GP
characteristics and across countries, a large proportion
of GPs reported that they would deprescribe at least one
medication in all scenarios. The odds of GPs reporting
decisions to deprescribe was higher in patients with a
higher dependency level (OR =1.5, 95%CI, 1.25 to 1.80)
and in absence of CVD history (OR =3.04, 95%CI 2.58
to 3.57). The medications GPs were most willing to
deprescribe in case vignettes with and without history of
CVD were pain medications and proton-pump inhibi-
tors. However, history of CVD appeared to affect
deprescribing decisions of certain medications. While
GPs were likely to deprescribe cholesterol medication
used for primary prevention (no history of CVD), GPs
were less likely to deprescribe those medications when
used for secondary prevention. Factors GPs rated as im-
portant or very important for deprescribing decisions
were patients’ quality of life, life expectancy, fear of po-
tential negative health outcomes resulting from depre-
scribing, and the risks and benefits of medications.
This is the first study to examine deprescribing deci-
sions of GPs across a large number of countries. We
found variation in deprescribing decisions across coun-
tries and based on GP characteristics, such as age with
older GPs being more likely to take deprescribing deci-
sions. Bolmsjö et al. (2016) found that deprescribing be-
haviours were largely dependent on the structure of
healthcare systems [35]. This might explain the differ-
ences we found between countries. Previous qualitative
studies reported that GPs with greater clinical experi-
ence were more able to draw on their own clinical
knowledge [36–39], which might explain why older and
more experienced GPs in our sample were more likely
to deprescribe. Further research is needed to explore the
association between GP characteristics and deprescribing
in more depth.
Our findings show that GPs were willing to depre-
scribe in patients with high dependency and increasing
cognitive impairment. The results built on a first analysis
with the Swiss data from the LESS study, in which we
had only included the most dependent, least robust
oldest-old adults (case vignette 3) and found that GPs
reported to be influenced by the risk and benefit of med-
ications, quality of life and life expectancy when taking
Table 2 Percentage of general practitioners (GPs) deprescribing in case vignettes, sorted by GPs’ decisions to deprescribe at least
one, two or three medications in the respective case vignette, patients’ level of dependency in activities of daily living, and patients’
history of cardiovascular disease (CVD) (N = 1,706)
Case vignette Patients’ dependency level Deprescribing
decision
Without history
of CVD (95% CI)
With history




(living in own house, no help needed
for activities of daily living)
min. 1 medication 95.1% (94.0 to 96.1) 81.6% (79.6 to 83.5) 13.5% (11.3 to 15.7)
min. 2 medications 88.2% (86.6 to 89.8) 60.1% (57.7 to 62.5) 28.1% (25.2 to 31.0)
min. 3 medications 69.2% (66.9 to 71.5) 26.5% (24.3 to 28.7) 42.7% (39.6 to 45.9)
2 medium
(living in own house, some help needed
for activities of daily living)
min. 1 medication 94.3% (93.1 to 95.5) 87.4% (85.7 to 89.1) 6.8% (4.8 to 8.9)
min. 2 medications 85.8% (84.0 to 87.5) 68.5% (66.1 to 70.9) 17.3% (14.3 to 20.3)
min. 3 medications 67.6% (65.3 to 70.0) 36.6% (34.1 to 39.1) 31.0% (27.6 to 34.5)
3 high
(living in nursing home, help needed for
nearly all activities of daily living)
min. 1 medication 94.1% (92.8 to 95.3) 90.4% (88.8 to 91.9) 3.7% (1.7 to 5.7)
min. 2 medications 88.5% (86.8 to 90.1) 79.2% (77.1 to 81.3) 9.3% (6.6 to 12.0)
min. 3 medications 78.4% (76.2 to 80.5) 58.6% (56.0 to 61.1) 19.8% (16.5 to 23.1)
aTwo-sample test of proportions
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deprescribing decisions [28]. Our findings are in line
with previous research, which revealed cognitive impair-
ment as an important factor for deprescribing [40]. This
also aligns with the basic principles of appropriate medi-
cation use which contend that potential benefits of the
medication should outweigh potential risks and align
with the goals of care of the individual [19]. As men-
tioned before, the benefit-risk profile of dependent and
less robust older adults is altered as they are at greater
risk of medication induced harm and may not have suffi-
cient remaining life span to benefit from preventive
medications [18, 19]. That GPs seem more willing to
deprescribe in older adults with increased dependency
levels implies that we need better ways to identify such
patients in primary care settings. The routine use of
frailty screening tools in primary care is gaining interest.
However, it remains unclear which tools are the most
useful and feasible and how to best deliver care for those
identified as frail and less robust [41, 42]. Furthermore,
despite the fact that certain tools exist to conduct depre-
scribing in older adults with frailty or limited life expect-
ancy, little is known about how such tools can be used
in a way that reduces inappropriate medication use and
improves clinical outcomes [43].
In line with a qualitative study by Luymes et al., we
found that GPs were more likely to deprescribe in pa-
tients with a lower CVD risk [33]. A recent national
cross-sectional survey of US geriatricians, general inter-
nists, and cardiologists found that > 90% of physicians in
each specialty reported to deprescribe cardiovascular
medications when patients experienced adverse drug re-
actions [44]. In addition, this study also pointed out po-
tential barriers linked to the communication between
physicians when making deprescribing decision. Our
finding of the impact of CVD on deprescribing, however,
is likely driven by the fact that four out of the seven
medications in the case vignette are related to the car-
diovascular system. Further research is warranted to find
ways to overcome the barriers linked to inter-
professional communication, as this is crucial for sus-
tainable deprescribing.
The medications presented in our case vignettes are
commonly used in older adults. However, some of them
are considered potentially inappropriate to be used in
older adults. For instance, according to the 2019 Beers
criteria aspirin should not be used for primary preven-
tion of cardiovascular disease, tramadol should be used
with caution as it may cause or exacerbate the syndrome
Table 3 Multilevel logistic regression model: adjusted effect of patient and general practitioners’ (GPs) characteristics on general
practitioners’ decisions to deprescribe at least one medication in any of the case vignettes (N = 1,706)
Overall
Odds ratio 95% confidence interval P-value
Patient’s history of cardiovascular disease (CVD)
History of CVD ref. – –
No history of CVD 3.04 2.58 to 3.57 < 0.001
Patient’s level of dependency in activities of daily living
Low ref. - -
Medium 1.29 1.09 to 1.55 0.004
High 1.50 1.25 to 1.80 < 0.001
Age (GP), 10-year increase 1.14 1.06 to 1.23 < 0.001
Female sex (GP) 0.89 0.75 to 1.05 0.167
Number of consultations per day
< 15 ref. – –
15–25 1.04 0.77 to 1.40 0.79
26–35 1.2 0.88 to 1.65 0.25
> 35 0.94 0.68 to 1.30 0.698
Frequency of seeing patients with polypharmacy
Never ref. – –
Rarely 0.64 0.18 to 2.28 0.497
Occasionally 0.80 0.25 to 2.53 0.699
Frequently 1.27 0.39 to 3.87 0.728
Very frequently 1.42 0.45 to 4.49 0.554
The multilevel model accounts for clustering of the GPs at country level
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of inappropriate secretion of antidiuretic hormone, and
the use of proton pump inhibitors for more than eight
weeks should be avoided in non-high-risk patients [45].
In this study, GPs were most likely to opt for deprescrib-
ing proton pump inhibitors and pain medication in case
vignettes with and without history of CVD while they
were least likely to deprescribe antihypertensive medica-
tions. GPs were also likely to deprescribe aspirin and
atorvastatin for primary prevention. This shows that GPs
in our sample were likely to opt for deprescribing medi-
cations that are potentially inappropriate when used in
older adults. This awareness needs to be built upon
when shifting deprescribing from theory to practice.
Generally reported deprescribing was high among the
GPs when considering the medications as a whole. How-
ever, the results for aspirin show that there remain
barriers to deprescribing even in hypothetical scenarios.
In 2018 three large studies established that aspirin for
primary prevention of CVD has a greater risk of harm
and shows relatively modest benefits in relation to car-
diovascular outcomes [46–48]. Therefore it would be in-
teresting to see whether our study would yield different
results (pertaining to aspirin) if it was repeated.
Further research is needed to create thorough guid-
ance on how to deprescribe in older adults with poten-
tially inappropriate polypharmacy, which includes
studying the safety of deprescribing in this population
group and to further investigate patient barriers to
deprescribing [28]. Over 70% of GPs in our study per-
ceive the existence of deprescribing guidelines and tools
that facilitate deprescribing as important or very import-
ant. This underscores the need for creating such
Table 4 Comparison of crude percentages of general practitioners (GPs) reporting to deprescribe the medications in the case
vignettes, sorted by medication type, history of cardiovascular disease (CVD), and dependency level (N = 1,706)







Percentage of GPs (95% CI) Percentage of GPs (95% CI) Percentage of GPs (95% CI)
Pain medications
Tramadol 50mg, twice daily
Without history of CVD 63.5% (61.1 to 65.9) 69.4% (67.0 to 71.7) 68.5% (66.0 to 70.9)
With history of CVD 57.3% (55.2 to 60.2) 67.0% (64.5 to 69.4) 67.6% (65.2 to 70.1)
Paracetamol 1 g, three times daily
Without history of CVD 47.5% (45.0 to 50.0) 41.9% (39.4 to 44.5) 44.9% (42.3 to 47.5)
With history of CVD 43.8% (41.3 to 46.3) 40.8% (38.3 to 43.4) 43.6% (41.0 to 46.2)
Proton-pump inhibitor
Pantoprazole 20mg, once daily
Without history of CVD 64.5% (63.0 to 67.8) 64.4% (61.9 to 66.8) 67.8% (65.3 to 70.2)
With history of CVD 47.1% (44.6 to 49.6) 49.0% (46.4 to 51.6) 55.6% (53.0 to 58.2)
Antihypertensive medications
Amlodipine 5mg, once daily
Without history of CVD 15.2% (13.4 to 17.0) 18.9% (17.0 to 21.0) 33.9% (31.4 to 36.4)
With history of CVD 8.7% (7.3 to 10.2) 15.1% (13.3 to 17.1) 30.3% (27.9 to 32.8)
Enalapril 10mg, once daily
Without history of CVD 7.7% (6.4 to 9.1) 9.8% (8.3 to 11.4) 19.4% (17.4 to 21.5)
With history of CVD 2.5% (1.7 to 3.4) 4.6% (3.6 to 5.8) 15.5% (13.6 to 17.5)
Cholesterol-lowering medication
Atorvastatin 40mg, once daily
Without history of CVD 59.1% (56.6 to 61.5) 62.7% (60.2 to 65.2) 76.8% (74.5 to 78.9)
With history of CVD 13.7% (12.0 to 15.5) 26.5% (24.3 to 28.9) 52.5% (49.9 to 55.1)
Antiplatelet medication
Aspirin 100mg, once daily
Without history of CVD 52.1% (49.6 to 54.5) 49.1% (46.5 to 51.7) 60.3% (57.7 to 62.8)
With history of CVD 4.3% (3.4 to 5.5) 7.2% (5.9 to 8.6) 23.9% (21.7 to 26.2)
Acronyms: CI Confidence interval; CVD Cardiovascular disease; GP General practitioner
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guidelines, not just on when to deprescribe but also how
to deprescribe. It also points to a need to raise awareness
of currently existing guidelines and potential benefits of
translating guidelines to local languages. Currently,
evidence-based deprescribing clinical practice guidelines
exist for proton pump inhibitors, benzodiazepines and
Z-drugs, antihyperglycemics, antipsychotics and cholin-
esterase inhibitors and memantine [49–53]. Further-
more, an in-depth exploration into the nuanced reasons
why GPs do or do not deprescribe specific medications
in specific situations and into how deprescribing could
be sustainably implemented will be useful for improving
deprescribing practices and guidelines.
Our study is strengthened by the inclusion of a large
number of GPs from many different countries in Europe
and beyond, some of which are rarely included in studies
among GPs. Furthermore, the average response rate of
53% is higher than typical response rates of 30–40% in
surveys among GPs [54]. The LESS study comes with
several limitations. The first one is the hypothetical na-
ture of our case vignettes, which were intended to estab-
lish and correspond to GPs’ routine clinical practice [28].
However, we were not able to capture the decision-
making process, including barriers and facilitators of
deprescribing, such as time limitations and patient prefer-
ences, values or goals of care, or capture the reasons why
GPs selected to deprescribe or not. Therefore, the results
of this study may not reflect the complex process of
shared decision making. That said, the simple nature of
the hypothetical case vignettes is also a strength, as it
allowed gathering of a large number of responses from
GPs in standardized cases. Second, we do not know how
reported deprescribing decisions would transfer to other
medications not included in the case vignettes. Third, we
did not randomly sample the GPs in each country but per-
formed a convenience sample based on the networks of
our national coordinators, which comes with limited
generalizability of our study results. Despite this, to
a
b
Fig. 2 Factors important to general practitioners (GPs) when making deprescribing decisions1, ordered by importance (N = 1,706). a) factors
related to the patient, and b) factors related to the GP. 1each GP was asked to rate the importance of each factor
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maximise the number of countries involved in order to in-
crease generalisability by reaching a larger number of GPs,
we allowed for variations in the types of networks that na-
tional co-ordinators used to recruit participants. The vari-
ation in the types of networks used was also reflected in
the large variation in response rates by country. In
addition, GPs self-selecting to complete the survey were
likely to be more interested in deprescribing, which may
mean that our results could be biased towards overesti-
mating deprescribing decisions. Fourth, we were limited
to the self-reported data about GPs’ deprescribing deci-
sions, which might have been affected by social desirability
bias and the order in which case vignettes were presented.
Fifth, we do not know to what extent the reported depre-
scribing decisions reflect or were influenced by national
deprescribing guidelines or other deprescribing initiatives.
Conclusions
Despite international variation, most GPs in our conveni-
ence sample reported they would deprescribe at least one
medication in hypothetical oldest-old multimorbid patients
with polypharmacy. Older GPs were more likely to take
deprescribing decisions. GPs were more likely to depre-
scribe in patients with a higher dependency in activities of
daily living and in the absence of a history of cardiovascular
disease. Overall, medications most often chosen for depre-
scribing in the presented case vignettes were proton pump
inhibitors and pain medications. Antiplatelet and
cholesterol-lowering medication was frequently selected for
deprescribing when used for primary prevention.
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